Fibrocell Science Inc

Fibrocell Science — Investor Presentation (April 2015)

21 slides from Fibrocell Science's investor presentation, Apr 21, 2015

  1. Slide 1: Fibrocell Corporate Presentation

    Fibrocell Corporate Presentation April 21, 2015 1

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forwar

  3. Slide 3: Investment Highlights

    • Fibrocell is the scientific leader of autologous fibroblast therapy for skin and connective tissue diseases • Developing a pipeline of gene therapies for orphan skin diseases using autologous fibroblasts to deliver the targeted gene • FCX-007: Novel gene-therapy drug candidate for Recessive Dystro

  4. Slide 4: The Science of Autologous Fibroblasts

    The Science of Autologous Fibroblasts • Fibroblasts repair tissue infrastructure by producing extracellular matrix proteins including collagen and growth factors • Most common cell in skin and connective tissue • Fibroblasts have distinct advantages for treatment of skin diseases ‐ Autologous cells

  5. Slide 5: Two Product Engines – Multiple Therapeutics in Development

    Gene Therapy Product Engine integrates Intrexon’s synthetic biology FCX-007, FCX-013 Autologous Fibroblast Product Engine azficel-T BLA Two Product Engines – Multiple Therapeutics in Development Collection Culture Local Administration Vector Preparation Gene Packaging Gene Transduction Personalized

  6. Slide 6: Key Relationships

    Key Relationships • Intrexon Corporation (NYSE: XON) – Development of gene therapies for orphan skin & connective tissue diseases • Stanford University – Lead center for development of FCX-007 • UCLA – Cell growth media research & development to optimize gene and cell therapies 6

  7. Slide 7: Development Pipeline

    Personalized Biologics Indication Pre-Clinical Development Phase 1 Phase 2 Phase 3 azficel-T sBLA Dysphonia FCX-007 Gene-Therapy Orphan Drug Candidate Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Gene-Therapy Orphan Drug Candidate Linear Scleroderma Development Pipeline 7

  8. Slide 8: Advantages of Our Approach

    Advantages of Our Approach • Criteria to pursue orphan indications: ‐ Unmet medical need ‐ Market opportunity/value proposition ‐ Technical feasibility ‐ Validated animal models ‐ Biologic precedent • Advantages of autologous fibroblast/gene-therapy approach: ‐ Localized injection (avoids systemic d

  9. Slide 9: Transforming Lives of RDEB Patients

    Transforming Lives of RDEB Patients 9

  10. Slide 10: Recessive Dystrophic Epidermolysis Bullosa

    Recessive Dystrophic Epidermolysis Bullosa • RDEB patients are not producing type VII collagen (COL7) due to mutation in COL7A1 gene ‐ Main component of anchoring fibrils that connect skin layers • Autologous human dermal fibroblasts transduced with a vector containing the gene for COL7A1 ‐ Administ

  11. Slide 11: Recessive Dystrophic Epidermolysis Bullosa: Disease, Treatments, Epidemiology

    Disease Current Treatments Epidemiology • Devastating, progressive, painful blistering disease that leads to death • Diagnosed at infancy • High mortality rate • Cause: A mutation in the COL7A1 gene which encodes for COL7 • Current treatments only address symptoms, not underlying disease • Bandaging

  12. Slide 12: FCX-007 Development Update

    FCX-007 Development Update Product Development Clinical Development Phase I Clinical Study Initiation, 2H 2015 IND Filing, mid-2015 Gained Clearance from Recombinant DNA Advisory Committee (RAC), Feb 2015 Pre-Clinical Studies – In Progress Pre-IND Meeting with FDA, Aug 2014 Orphan Drug Approval, Jun

  13. Slide 13: Research Studies Support Our Approach in RDEB

    • Multiple published studies in previous animal models4,5,6 demonstrate that fibroblasts genetically modified with COL7A1 ‐ Deposited type VII collagen and formed anchoring fibrils at the dermal-epidermal junction ‐ Exhibited stable expression ‐ Corrected blistering • Autologous cells are preferred

  14. Slide 14: Rationale Supporting Our Approach in RDEB

    • Precedent for FDA-allowed IND using GM cells to treat RDEB ‐ A Stanford Phase I clinical trial (NIH-funded) using autologous keratinocyte sheets genetically modified with COL7A1 to treat RDEB is ongoing 9 ‐ Establishes a basis and precedent pathway for our Phase I clinical trial design for FCX-007

  15. Slide 15: Linear Scleroderma

    Disease Epidemiology • Excess production of extracellular matrix characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions appearing across joint

  16. Slide 16: Dysphonia

    Disease Current Treatments Epidemiology Damage to the fibroblast layer causes scarring and edema which limits air flow and results in severe and significant limitations in voice quality, often loss of voice • Current treatments only address symptoms, not underlying disease • Voice therapy • Surgery

  17. Slide 17: Clinical Data Support Our Approach in Dysphonia

    Positive Phase I clinical trial results published in peer-reviewed journal13 • All patients completed the clinical trial, successive injections of autologous fibroblasts were well-tolerated, and no serious adverse events reported; n=5 • Statistically significant and sustained improvement – Efficacy

  18. Slide 18: Dysphonia Phase II

    • Enrollment of 22 subjects as of 21 April 2015 • Multi-center trial: 3 major sites • Double-blind, randomized, placebo-controlled, 20 subjects • Validated scales with a 4-month efficacy endpoint • Dosing expected to be complete by year end Dysphonia Phase II 18

  19. Slide 19: Financial and Corporate Information

    • Cash = $37.5 million at 31 Dec 2014 • NASDAQ listed: FCSC • 41 million common shares outstanding - 6.0 million warrants; 2.1 million options • Analyst research - Wedbush Securities — David Nierengarten, PhD - Griffin Securities — Keith Markey, PhD • HQ facility: Exton, PA • ~50 employees Financial

  20. Slide 20: Investment Highlights

    • Fibrocell is the scientific leader of autologous fibroblast therapy for skin and connective tissue diseases • Developing a pipeline of gene therapies for orphan skin diseases using autologous fibroblasts to deliver the targeted gene • FCX-007: Novel gene-therapy drug candidate for Recessive Dystro

  21. Slide 21: References

    References 1DEBRA International DEBRA International. What is EB Infographic. http://www.debra- international.org/epidermolysis-bullosa.html. Accessed 10/06/2014. 2 Petrof G., et. al. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a r

Fibrocell Science — Investor Presentation (April 2015) on 6ix